Logo image of SPRY

ARS PHARMACEUTICALS INC (SPRY) Stock Fundamental Analysis

NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD

11.24  -0.54 (-4.58%)

After market: 11.21 -0.03 (-0.27%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SPRY. SPRY was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SPRY as it has an excellent financial health rating, but there are worries on the profitability. SPRY is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SPRY had negative earnings in the past year.
In the past year SPRY has reported a negative cash flow from operations.
In the past 5 years SPRY always reported negative net income.
SPRY had a negative operating cash flow in each of the past 5 years.
SPRY Yearly Net Income VS EBIT VS OCF VS FCFSPRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

SPRY's Return On Assets of -22.57% is fine compared to the rest of the industry. SPRY outperforms 74.42% of its industry peers.
SPRY has a better Return On Equity (-24.43%) than 82.42% of its industry peers.
Industry RankSector Rank
ROA -22.57%
ROE -24.43%
ROIC N/A
ROA(3y)-20.82%
ROA(5y)-44.89%
ROE(3y)-21.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SPRY Yearly ROA, ROE, ROICSPRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 -200 400

1.3 Margins

SPRY does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRY Yearly Profit, Operating, Gross MarginsSPRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -50K -100K -150K -200K

More info and screens

8

2. Health

2.1 Basic Checks

SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRY has been increased compared to 1 year ago.
Compared to 5 years ago, SPRY has more shares outstanding
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SPRY Yearly Shares OutstandingSPRY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
SPRY Yearly Total Debt VS Total AssetsSPRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 38.47 indicates that SPRY is not in any danger for bankruptcy at the moment.
SPRY's Altman-Z score of 38.47 is amongst the best of the industry. SPRY outperforms 97.16% of its industry peers.
SPRY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 38.47
ROIC/WACCN/A
WACC9.44%
SPRY Yearly LT Debt VS Equity VS FCFSPRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

SPRY has a Current Ratio of 12.56. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.
SPRY has a Current ratio of 12.56. This is amongst the best in the industry. SPRY outperforms 84.72% of its industry peers.
A Quick Ratio of 12.52 indicates that SPRY has no problem at all paying its short term obligations.
The Quick ratio of SPRY (12.52) is better than 84.90% of its industry peers.
Industry RankSector Rank
Current Ratio 12.56
Quick Ratio 12.52
SPRY Yearly Current Assets VS Current LiabilitesSPRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SPRY have decreased strongly by -288.89% in the last year.
The Revenue has grown by 90.22% in the past year. This is a very strong growth!
EPS 1Y (TTM)-288.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)90.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 34.20% on average over the next years. This is a very strong growth
SPRY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 765.27% yearly.
EPS Next Y-3.34%
EPS Next 2Y17.01%
EPS Next 3Y27.84%
EPS Next 5Y34.2%
Revenue Next Year180292%
Revenue Next 2Y11018.3%
Revenue Next 3Y2707.44%
Revenue Next 5Y765.27%

3.3 Evolution

SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SPRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SPRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRY Price Earnings VS Forward Price EarningsSPRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRY Per share dataSPRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as SPRY's earnings are expected to grow with 27.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.01%
EPS Next 3Y27.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (2/21/2025, 8:00:02 PM)

After market: 11.21 -0.03 (-0.27%)

11.24

-0.54 (-4.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-20 2025-03-20/amc
Inst Owners66.89%
Inst Owner ChangeN/A
Ins Owners18.28%
Ins Owner Change-0.76%
Market Cap1.09B
Analysts88
Price Target33.15 (194.93%)
Short Float %22.15%
Short Ratio11.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.09%
Min EPS beat(2)-32.93%
Max EPS beat(2)-9.24%
EPS beat(4)2
Avg EPS beat(4)2.69%
Min EPS beat(4)-32.93%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)88.8%
EPS beat(12)6
Avg EPS beat(12)53.26%
EPS beat(16)7
Avg EPS beat(16)24.54%
Revenue beat(2)1
Avg Revenue beat(2)100.81%
Min Revenue beat(2)-50.98%
Max Revenue beat(2)252.6%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.07%
PT rev (3m)18.9%
EPS NQ rev (1m)-103.7%
EPS NQ rev (3m)12.7%
EPS NY rev (1m)0.86%
EPS NY rev (3m)10.12%
Revenue NQ rev (1m)-31.02%
Revenue NQ rev (3m)4.88%
Revenue NY rev (1m)-9.09%
Revenue NY rev (3m)181.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 425.4
P/FCF N/A
P/OCF N/A
P/B 5.44
P/tB 5.65
EV/EBITDA N/A
EPS(TTM)-0.51
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.47
FCFYN/A
OCF(TTM)-0.47
OCFYN/A
SpS0.03
BVpS2.07
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.57%
ROE -24.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.82%
ROA(5y)-44.89%
ROE(3y)-21.59%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 263.49%
Cap/Sales 6.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.56
Quick Ratio 12.52
Altman-Z 38.47
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)159.29%
Cap/Depr(5y)128.03%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-288.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-3.34%
EPS Next 2Y17.01%
EPS Next 3Y27.84%
EPS Next 5Y34.2%
Revenue 1Y (TTM)90.22%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year180292%
Revenue Next 2Y11018.3%
Revenue Next 3Y2707.44%
Revenue Next 5Y765.27%
EBIT growth 1Y-92.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.18%
EBIT Next 3Y51.13%
EBIT Next 5YN/A
FCF growth 1Y37.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.99%
OCF growth 3YN/A
OCF growth 5YN/A